@IntensityInc profile picture
Intensity Therapeutics @IntensityInc
Joined February 2013
  • Tweets 722
  • Following 256
  • Followers 961
140 Photos and videos
$INTS reported Q1 2026 financial results & a corporate update, including favorable preliminary observations from the Phase 2 INVINCIBLE-4 study in #TNBC. #INTS also plans to resume enrollment in the Phase 3 INVINCIBLE-3 sarcoma study by Q3 2026. Full PR: bit.ly/4tkZLQC
Intensity Therapeutics graphic announcing first quarter 2026 financial results and a corporate update, highlighting $10.2 million in cash, favorable preliminary Phase 2 INVINCIBLE-4 observations in TNBC, and plans to resume enrollment in the INVINCIBLE-4 and INVINCIBLE-3 studies in 2026.

ALT Intensity Therapeutics graphic announcing first quarter 2026 financial results and a corporate update, highlighting $10.2 million in cash, favorable preliminary Phase 2 INVINCIBLE-4 observations in TNBC, and plans to resume enrollment in the INVINCIBLE-4 and INVINCIBLE-3 studies in 2026.
3
14
1,056
This #InternationalBiotechDay, $INTS recognizes the scientists, researchers, and innovators advancing the next generation of cancer therapies. #BiotechDay
0:07
5
47
#Breastcancer is the most common cancer diagnosed in women in the US. Raising awareness and advancing cancer research remain critical to improving outcomes for patients affected by cancer. $INTS @AmericanCancer
1
1
12
372
INT230-6 has demonstrated broad tumor dispersion, reductions in viable tumor cells, and increased immune cell infiltration across multiple cancer types. These data further support INT230-6's novel approach to local tumor treatment and immune activation. $INTS
3
16
567
Highlighting $INTS' senior management team. With deep experience across #biotech and drug development, the team continues advancing Intensity's mission in cancer treatment innovation. Learn more: bit.ly/4l3PrbU
Graphic from Intensity Therapeutics featuring the company’s senior management team, including headshots and titles for Lewis H. Bender, Joseph Talam, James M. Ahlers, John Wesolowski, Kimberly A. Guedes, and Doranne Frano.

ALT Graphic from Intensity Therapeutics featuring the company’s senior management team, including headshots and titles for Lewis H. Bender, Joseph Talam, James M. Ahlers, John Wesolowski, Kimberly A. Guedes, and Doranne Frano.

2
2
15
557
#ICYMI: Lewis Bender, CEO of $INTS, recently shared insights with Biopharma Boardroom on the potential of INT230-6 and the evolving future of intratumoral therapies. Catch up here: bit.ly/3OiA6JY

Reprogramming the Tumor: Lew Bender on Engineering a New Paradigm in Cancer Therapy

Lew Bender, Founder and CEO of Intensity Therapeutics, discusses how INT230-6 is redefining intratumoral therapy—bridging cytotoxic precision with immune activation to overcome the limitations of...

biopharmaboardroom.com
2
2
12
733
$INTS' Founder & CEO, Lewis Bender, reflected on the Company’s recent recognition as the 2026 Cancer Treatment Technology Innovator Award winner. See the @Global_H_Pharma award winners: bit.ly/4wFAdR9 #GHPAward
0:08
1
9
386
May is #NationalCancerResearchMonth, underscoring the role of  #cancerresearch in advancing new treatments. $INTS is advancing a novel intratumoral approach to treat cancer at any stage, activating a systemic immune response. #NCRMonth #Oncology
Graphic with colorful cancer awareness ribbons surrounding the text “May is National Cancer Research Month” in green lettering, alongside the Intensity Therapeutics logo on a light gray background.

ALT Graphic with colorful cancer awareness ribbons surrounding the text “May is National Cancer Research Month” in green lettering, alongside the Intensity Therapeutics logo on a light gray background.
1
9
340
This fall, $INTS will participate in the Novel Modalities stream at @BostonDOT. On Oct. 1 at 4:05 PM, #INTS Founder & CEO Lewis Bender will present on advances in intratumoral drug delivery and tumor uptake of anticancer agents. Learn more: bit.ly/4wczRBr #BostonDOT
2
14
626
$INTS is proud to share we’ve received the @Global_H_Pharma 2026 Cancer Treatment Technology Innovator Award! #INTS is advancing an intratumoral approach to treat tumors locally and activate a systemic immune response. Honored to be included. Read more: bit.ly/3Ph8q92 #GHPAward
Graphic announcing that Intensity Therapeutics received GHP Magazine’s 2026 Healthcare & Pharmaceutical Award. The image includes an award badge recognizing the company as “Cancer Treatment Technology Innovator of the Year 2026 – USA” and features the Intensity Therapeutics logo.

ALT Graphic announcing that Intensity Therapeutics received GHP Magazine’s 2026 Healthcare & Pharmaceutical Award. The image includes an award badge recognizing the company as “Cancer Treatment Technology Innovator of the Year 2026 – USA” and features the Intensity Therapeutics logo.

2
3
14
578
National Women’s Health Week highlights the need for progress in #breastcancer. $INTS is advancing an intratumoral approach in #TNBC to treat tumors locally & activate a systemic immune response. Innovation in #womenhealth remains critical to improving patient outcomes. #NWHW
Graphic with the text “National Women’s Health Week” and “May 10th-16th” in dark green lettering on a light green background, featuring silhouettes of women in varying shades of gray and the Intensity Therapeutics logo at the bottom.

ALT Graphic with the text “National Women’s Health Week” and “May 10th-16th” in dark green lettering on a light green background, featuring silhouettes of women in varying shades of gray and the Intensity Therapeutics logo at the bottom.

1
13
389
Intensity Therapeutics retweeted
Intensity Therapeutics
@IntensityInc
May 1
Last night, $INTS attended @Runway4Recovery's Runway Show NYC in support of #breastcancerawareness. #INTS' CEO Lew Bender, joined Eve Bender, VP of sales at @FValentineNY, who dressed five models for the event. An inspiring evening honoring those impacted. #RunwayForRecovery
2
11
627
Intensity Therapeutics retweeted
Intensity Therapeutics
@IntensityInc
May 1
About 350,000 women are diagnosed with breast cancer annually. The Runway Show last night was a powerful celebration of 85 women who beat or are fighting #breastcancer, including my sister. Intensity remains committed to developing a new drug that someday will help more BC patients live healthier, longer lives. - ‌Lewis Bender
2
16
438
Tonight, $INTS is attending the 2nd Annual Runway Show NYC with @Runway4Recovery. 85 survivors will take the runway, with @katiecouric as Spotlight Model. Proud to support. #RunwayForRecovery
Graphic with Intensity Therapeutics logo over a blurred runway background. Text reads: “We’re Attending The Runway Show, New York City.” Event details: April 30, 2026 at Chelsea Piers, New York City. Runway for Recovery (R4R) logo displayed at the bottom.

ALT Graphic with Intensity Therapeutics logo over a blurred runway background. Text reads: “We’re Attending The Runway Show, New York City.” Event details: April 30, 2026 at Chelsea Piers, New York City. Runway for Recovery (R4R) logo displayed at the bottom.
1
11
666
$INTS' VP Clinical Ops, Kimberly A. Guedes, will join @PrecisionEvolu1's Clinical Trials Summit in Boston starting today for a fireside chat on addressing trial risk earlier in development. #PCSummit #LeadershipInsights
1
10
260
New approaches are needed to treat #cancer at every stage. $INTS is developing an #intratumoral platform designed to target tumors directly while supporting a broader immune response. Learn more: bit.ly/47qAopx
Graphic from Intensity Therapeutics with the headline “Treat Cancer at Any Stage” and subhead “Treat locally. Act globally.” Text explains a novel intratumoral approach designed to kill cancer cells and enable immune cells to attack tumors throughout the body. Image shows a clinician administering an injection into a patient’s arm.

ALT Graphic from Intensity Therapeutics with the headline “Treat Cancer at Any Stage” and subhead “Treat locally. Act globally.” Text explains a novel intratumoral approach designed to kill cancer cells and enable immune cells to attack tumors throughout the body. Image shows a clinician administering an injection into a patient’s arm.
1
16
333
For decades, #solidtumors have been difficult to treat due to their dense structure and protective microenvironment. CEO Lew Bender discusses how $INTS is developing intratumoral therapies to target tumors directly and overcome these barriers. Read more: bit.ly/3Nu2mJf
0:16
12
522
$INTS recently shared a Phase 2 INVINCIBLE-4 update for INT230-6 in #TNBC. Preliminary observations showed higher pCR and fewer high-grade AEs vs SOC. Enrollment restart pending. Read more: bit.ly/4lpFI13 #ClinicalTrials
Graphic titled “INT230-6 Clinical Progress” highlighting Phase 2 INVINCIBLE-4 updates: 71.4% pCR, 44% fewer Grade ≥3 adverse events, and enrollment restart pending review, with a surgical background.

ALT Graphic titled “INT230-6 Clinical Progress” highlighting Phase 2 INVINCIBLE-4 updates: 71.4% pCR, 44% fewer Grade ≥3 adverse events, and enrollment restart pending review, with a surgical background.
1
11
504
Load more